BioDelivery Sciences International (BDSI) Rating Lowered to Sell at BidaskClub

BioDelivery Sciences International (NASDAQ:BDSI) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

BDSI has been the subject of a number of other research reports. Cantor Fitzgerald set a $5.00 price target on BioDelivery Sciences International and gave the company a “buy” rating in a research note on Sunday, October 7th. Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Wednesday, October 3rd. Janney Montgomery Scott boosted their price target on BioDelivery Sciences International to $5.00 and gave the company a “buy” rating in a research note on Friday, November 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of BioDelivery Sciences International in a research note on Friday, November 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. BioDelivery Sciences International currently has an average rating of “Buy” and an average target price of $4.54.

Get BioDelivery Sciences International alerts:

BDSI stock opened at $3.65 on Friday. BioDelivery Sciences International has a 52 week low of $1.70 and a 52 week high of $4.14. The company has a quick ratio of 2.77, a current ratio of 3.00 and a debt-to-equity ratio of 1.42.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.04. The business had revenue of $14.16 million during the quarter, compared to the consensus estimate of $14.21 million. BioDelivery Sciences International had a negative return on equity of 141.35% and a negative net margin of 85.93%. On average, equities analysts anticipate that BioDelivery Sciences International will post -0.61 EPS for the current fiscal year.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 151,039 shares of BioDelivery Sciences International stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $2.84, for a total value of $428,950.76. Following the transaction, the director now owns 520,482 shares in the company, valued at $1,478,168.88. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $3.84, for a total value of $30,720.00. Following the completion of the transaction, the director now owns 522,187 shares in the company, valued at approximately $2,005,198.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 167,039 shares of company stock valued at $481,671. 13.26% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can bought a new position in BioDelivery Sciences International in the second quarter valued at about $138,000. PNC Financial Services Group Inc. bought a new position in BioDelivery Sciences International in the second quarter valued at about $148,000. Worth Venture Partners LLC bought a new position in BioDelivery Sciences International in the third quarter valued at about $167,000. Dimensional Fund Advisors LP bought a new position in BioDelivery Sciences International in the third quarter valued at about $255,000. Finally, Wells Fargo & Company MN grew its position in BioDelivery Sciences International by 121.7% in the third quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock valued at $331,000 after acquiring an additional 64,803 shares during the last quarter. Hedge funds and other institutional investors own 44.01% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.